New hope for tough lupus cases? early trial of UB-VV410 begins
NCT ID NCT07109986
First seen Jan 26, 2026 · Last updated Apr 29, 2026 · Updated 15 times
Summary
This early-stage study tests a new drug, UB-VV410, in 21 adults with active lupus (including kidney inflammation) that hasn't responded to standard treatments. The main goals are to check safety and find the best dose. Researchers will also look for signs that the drug helps control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Nanjing Medical University
RECRUITINGNanjing, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.